Asian Market Value Stock Estimates For March 2025
As global markets grapple with economic uncertainty and inflation concerns, the Asian markets have shown resilience, with investors keenly eyeing value stocks that may offer stability amid volatility. In this context, identifying undervalued stocks in Asia could provide opportunities for those looking to navigate these challenging times by focusing on companies with strong fundamentals and potential for growth.
Name
Current Price
Fair Value (Est)
Discount (Est)
DIP (TSE:2379)
¥2299.00
¥4575.97
49.8%
Zhejiang Cfmoto PowerLtd (SHSE:603129)
CN¥183.48
CN¥359.71
49%
Consun Pharmaceutical Group (SEHK:1681)
HK$8.95
HK$17.64
49.3%
Chison Medical Technologies (SHSE:688358)
CN¥31.17
CN¥61.59
49.4%
RACCOON HOLDINGS (TSE:3031)
¥965.00
¥1893.98
49%
TechnoPro Holdings (TSE:6028)
¥3301.00
¥6597.88
50%
S Foods (TSE:2292)
¥2544.00
¥5084.09
50%
Com2uS (KOSDAQ:A078340)
₩45950.00
₩91675.96
49.9%
Siam Wellness Group (SET:SPA)
THB4.58
THB9.12
49.8%
Akeso (SEHK:9926)
HK$74.60
HK$147.04
49.3%
Click here to see the full list of 276 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
Let's review some notable picks from our screened stocks.
Overview: PharmaResearch Co., Ltd., along with its subsidiaries, is a biopharmaceutical company operating mainly in South Korea with a market cap of approximately ₩3.51 trillion.
Operations: PharmaResearch Co., Ltd.'s revenue segments are not detailed in the provided text.
Estimated Discount To Fair Value: 15.4%
PharmaResearch is trading at ₩337,500, below its estimated fair value of ₩398,985.63. With forecasted revenue growth of 20.4% per year outpacing the Korean market's 8.1%, and earnings expected to grow significantly at 26.8% annually, the stock appears undervalued based on cash flows despite not being highly undervalued by a significant margin. Recent dividend increases further reflect confidence in its financial health and future prospects.
Our comprehensive growth report raises the possibility that PharmaResearch is poised for substantial financial growth.
Click to explore a detailed breakdown of our findings in PharmaResearch's balance sheet health report.
Overview: Seres Group Co., Ltd. is engaged in the research, development, manufacturing, sale, and supply of automobiles and auto parts in China with a market capitalization of CN¥191.38 billion.
Operations: The company's revenue from the automobile industry amounts to CN¥125.79 billion.
Estimated Discount To Fair Value: 17.6%
Seres Group Ltd. is trading at CN¥127.08, below its estimated fair value of CN¥154.2, indicating it is undervalued based on cash flows though not by a significant margin. The company's earnings are forecast to grow significantly at 33.6% annually, outpacing the Chinese market average of 25%. With revenue growth expected at 16.2% per year and a high forecasted return on equity of 33.7%, Seres demonstrates strong financial potential despite recent profitability challenges.
The growth report we've compiled suggests that Seres GroupLtd's future prospects could be on the up.
Unlock comprehensive insights into our analysis of Seres GroupLtd stock in this financial health report.
Overview: Wuhan Keqian Biology Co., Ltd specializes in the R&D, production, sales, and technical services for animal epidemic prevention through veterinary biological products in China, with a market cap of CN¥7.36 billion.
Operations: The company's revenue primarily comes from the Veterinary Biological Products Industry, amounting to CN¥947.87 million.
Estimated Discount To Fair Value: 29.2%
Wuhan Keqian Biology Ltd. is trading at CN¥15.84, significantly below its estimated fair value of CN¥22.38, highlighting its undervaluation based on cash flows. The company forecasts robust revenue growth of 22.8% annually, surpassing the Chinese market's average growth rate of 13%. Despite a recent decline in sales and net income for 2024, earnings are projected to grow at approximately 21% per year over the next three years, though slower than the market's expected pace.
Insights from our recent growth report point to a promising forecast for Wuhan Keqian BiologyLtd's business outlook.
Delve into the full analysis health report here for a deeper understanding of Wuhan Keqian BiologyLtd.
Embark on your investment journey to our 276 Undervalued Asian Stocks Based On Cash Flows selection here.
Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A214450 SHSE:601127 and SHSE:688526.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Dollarama Inc. Just Beat EPS By 17%: Here's What Analysts Think Will Happen Next
Shareholders of Dollarama Inc. (TSE:DOL) will be pleased this week, given that the stock price is up 10% to CA$194 following its latest first-quarter results. It looks like a credible result overall - although revenues of CA$1.5b were in line with what the analysts predicted, Dollarama surprised by delivering a statutory profit of CA$0.98 per share, a notable 17% above expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Taking into account the latest results, the consensus forecast from Dollarama's eleven analysts is for revenues of CA$6.78b in 2026. This reflects a reasonable 3.9% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to accumulate 4.4% to CA$4.62. Before this earnings report, the analysts had been forecasting revenues of CA$6.75b and earnings per share (EPS) of CA$4.51 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates. See our latest analysis for Dollarama The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 17% to CA$197. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Dollarama analyst has a price target of CA$223 per share, while the most pessimistic values it at CA$115. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view. Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that Dollarama's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 5.2% growth on an annualised basis. This is compared to a historical growth rate of 12% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 9.1% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Dollarama. The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Dollarama's earnings potential next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Dollarama going out to 2028, and you can see them free on our platform here. Plus, you should also learn about the 2 warning signs we've spotted with Dollarama . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New York Post
14 hours ago
- New York Post
North Korea relaunches 5K ton warship after embarrassing false start in May
North Korea has successfully repaired and relaunched its new 5,000-ton naval destroyer less than a month after the boat embarrassingly capsized, according to state media reports. The Korean Central News Agency said the destroyer — the second one Pyongyang has built this year — was back in the water on Thursday. 3 Kim Jong Un brought his daughter along for the relaunch. KCNA VIA KNS/AFP via Getty Images The reclusive North Korean leader Kim Jong Un was reportedly at the launch, held along the country's east coast. Kim said the new battleship stood as 'convincing proof of the rapid transformation of our Navy. … No one will doubt, I think, the rapid transformation of our Navy as they have witnessed the launching of another new-type destroyer less than two months after a similar event at the Nampho Shipyard.' Kim repeated prior claims he would bolster North Korea's navy in response to perceived threats posed by the US and its Asian allies. 3 Kim and his daughter toured the warship on Thursday. KCNA/EPA-EFE/Shutterstock 'The super-radical growth of our Navy's operations capability is now being proved by powerful entities, not by a prediction or possibility, and this has already become an unstoppable, powerful current of history,' said Kim. The ruler of the hermit kingdom previously attributed last month's botched launch to criminal negligence. Four officials were later detained, including the vice director of the Workers' Party's munitions industry department. 3 This is the second destroyer the reclusive nation's built this year. KCNA VIA KNS/AFP via Getty Images Meanwhile, Kim has been visiting military industrial factories across the country, calling on the country to ramp up production of shells in order to meet the demands of war in the 21st century. KCNP reported Kim 'gave field guidance at a major munitions industry enterprise' on Friday, and 'learned in detail about shell production, capacity expansion and modernization projects in the first half of 2025.' Kim 'expressed great satisfaction over the high enthusiasm for patriotic deeds and struggle displayed by the workers at the enterprise,' KCNP reported. He further noted stepping up production would 'satisfy all the requirements of the national defence strategy and increase the output of new-type powerful shells to meet the requirements of modern warfare.'
Yahoo
20 hours ago
- Yahoo
Why The 30% Return On Capital At Headwater Exploration (TSE:HWX) Should Have Your Attention
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. So when we looked at the ROCE trend of Headwater Exploration (TSE:HWX) we really liked what we saw. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on Headwater Exploration is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.30 = CA$257m ÷ (CA$967m - CA$115m) (Based on the trailing twelve months to March 2025). Thus, Headwater Exploration has an ROCE of 30%. That's a fantastic return and not only that, it outpaces the average of 9.8% earned by companies in a similar industry. View our latest analysis for Headwater Exploration Above you can see how the current ROCE for Headwater Exploration compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Headwater Exploration for free. The fact that Headwater Exploration is now generating some pre-tax profits from its prior investments is very encouraging. Shareholders would no doubt be pleased with this because the business was loss-making five years ago but is is now generating 30% on its capital. In addition to that, Headwater Exploration is employing 407% more capital than previously which is expected of a company that's trying to break into profitability. This can indicate that there's plenty of opportunities to invest capital internally and at ever higher rates, both common traits of a multi-bagger. For the record though, there was a noticeable increase in the company's current liabilities over the period, so we would attribute some of the ROCE growth to that. Essentially the business now has suppliers or short-term creditors funding about 12% of its operations, which isn't ideal. It's worth keeping an eye on this because as the percentage of current liabilities to total assets increases, some aspects of risk also increase. Long story short, we're delighted to see that Headwater Exploration's reinvestment activities have paid off and the company is now profitable. And a remarkable 572% total return over the last five years tells us that investors are expecting more good things to come in the future. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence. If you'd like to know more about Headwater Exploration, we've spotted 2 warning signs, and 1 of them is concerning. If you'd like to see other companies earning high returns, check out our free list of companies earning high returns with solid balance sheets here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
